Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: pater tenebrarum who wrote (146295)	1/26/2002 12:26:35 AM
From: LLCF	Read Replies (3) \| Respond to of 436258

Heinz, I'd be careful with this one... there are lots of antiangiogenesis candidates around, and Folkman may be as much hype as meat. I'd consult with the biotech experts here on SI if I were you, I can tell you who to book mark if you wish. DDAK

To: pater tenebrarum who wrote (146295)	1/26/2002 8:44:28 PM
From: Spekulatius	Read Replies (2) \| Respond to of 436258

ENMD - Endostatin, ENMD's antiangiogeneis drug for cancer shown mixed results in clinical trials. Also keep in mind that BMY backed out of a collaboration with ENMD. In general, the anti-angiogenesis field is currently not that hot, because compounds so far have not shown clear clinical benefits in monotherapy clinical trials. Most likely, anti-angiogensis compounds will end up being part of a "cocktail" approach to fight cancer, but it will take a long time to convince the FDA about the clinical benefits, IMO.

To: pater tenebrarum who wrote (146295)	1/26/2002 8:45:20 PM
From: Spekulatius	Respond to of 436258

ENMD - Endostatin, ENMD's antiangiogeneis drug for cancer shown mixed results in clinical trials. Also keep in mind that BMY backed out of a collaboration with ENMD. In general, the anti-angiogenesis field is currently not that hot, because compounds so far have not shown clear clinical benefits in monotherapy clinical trials. Most likely, anti-angiogenesis compounds will end up being part of a "cocktail" approach to fight cancer, but it will take a long time to convince the FDA about the clinical benefits, IMO.